FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4385462511> ?p ?o ?g. }

• W4385462511 endingPage "109839" @default.
• W4385462511 startingPage "109839" @default.
• W4385462511 abstract "Background and PurposeThe addition of cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) to endocrine therapy in hormone receptor-positive (HR+) human epidermal growth factor 2-negative (HER2-) breast cancer has led to practice-changing improvements in overall survival. However, there are conflicting data concerning the safety of CDK4/6i combination with radiotherapy, and no consensus guidelines exist to guide practice. We conducted a meta-analysis to assess the safety and feasibility of CDK4/6i treatment with radiotherapy.Materials and MethodsA comprehensive search was performed in PubMed/MEDLINE, Web of Science, and Scopus, for studies in advanced/metastatic breast cancer receiving CDK4/6i and radiotherapy with the provided safety data on the occurrence of toxicity. The main outcomes were safety (grade 3-5 adverse events), CDK 4/6i dose reduction, and the discontinuation rate due to toxicity.ResultsFifteen studies comprising 1133 patients with HR+/HER2- breast cancer patients were included. Among them, 617 pts received CDK4/6i and radiotherapy; the median follow-up was 17.0 months (IQR 9.2 – 18.0), and the median age was 58.8 years (IQR 55.5 - 62.5). The pooled prevalence of severe hematologic toxicity was 29.4% (95% CI 14.0% – 47.4%; I2 = 93%; τ2 = 0.084; p < 0.01 and severe non-hematologic toxicity was 2.8% (95% CI 1.1% – 4.8%; I2 = 0%; τ2 = 0.0; p = 0.67). The pooled prevalence of CDK4/6i dose reduction was 24.0% (95% CI 11.1% – 39.4%; I2 = 90%; τ2 = 0.052; p < 0.01) with no difference between CDK4/6i plus RT vs. CDK4/6i (odds ratio of 0.934; 95% CI 0.66 – 1.33; I2 = 0%; τ2 = 0.0; p = 0.56). The pooled prevalence of CDK4/6i discontinuation due to toxicity was 2.3% (95% CI 0.4% – 5.2%; I2 = 23%; τ2 = 0.002; p = 0.24).ConclusionThe findings of this study suggest that radiotherapy in addition to CDK4/6i treatment in breast cancer patients is generally safe and well tolerated and remains a viable treatment option." @default.
• W4385462511 created "2023-08-02" @default.
• W4385462511 creator A5014286562 @default.
• W4385462511 creator A5023706702 @default.
• W4385462511 creator A5023916915 @default.
• W4385462511 creator A5030442889 @default.
• W4385462511 creator A5036606080 @default.
• W4385462511 creator A5041249091 @default.
• W4385462511 date "2023-10-01" @default.
• W4385462511 modified "2023-10-03" @default.
• W4385462511 title "Safety and feasibility of CDK4/6 inhibitors treatment combined with radiotherapy in patients with HR-positive/HER2-negative breast cancer. A systematic review and meta-analysis" @default.
• W4385462511 cites W1596902544 @default.
• W4385462511 cites W1967504364 @default.
• W4385462511 cites W2043945205 @default.
• W4385462511 cites W2136158663 @default.
• W4385462511 cites W2526664649 @default.
• W4385462511 cites W2624918496 @default.
• W4385462511 cites W2742499689 @default.
• W4385462511 cites W2757215022 @default.
• W4385462511 cites W2768722765 @default.
• W4385462511 cites W2799401639 @default.
• W4385462511 cites W2885203907 @default.
• W4385462511 cites W2889646458 @default.
• W4385462511 cites W2896251702 @default.
• W4385462511 cites W2912931586 @default.
• W4385462511 cites W2926649918 @default.
• W4385462511 cites W2944314786 @default.
• W4385462511 cites W2968195098 @default.
• W4385462511 cites W2996719003 @default.
• W4385462511 cites W3032579401 @default.
• W4385462511 cites W3032651552 @default.
• W4385462511 cites W3037517728 @default.
• W4385462511 cites W3093675164 @default.
• W4385462511 cites W3108225937 @default.
• W4385462511 cites W3172158418 @default.
• W4385462511 cites W3172414849 @default.
• W4385462511 cites W3174841530 @default.
• W4385462511 cites W3185868618 @default.
• W4385462511 cites W3201166623 @default.
• W4385462511 cites W3206923034 @default.
• W4385462511 cites W3207557929 @default.
• W4385462511 cites W4206666777 @default.
• W4385462511 cites W4286510380 @default.
• W4385462511 cites W4293116439 @default.
• W4385462511 cites W4306393509 @default.
• W4385462511 cites W4307721600 @default.
• W4385462511 cites W4308731659 @default.
• W4385462511 cites W4317743601 @default.
• W4385462511 doi "https://doi.org/10.1016/j.radonc.2023.109839" @default.
• W4385462511 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37536378" @default.
• W4385462511 hasPublicationYear "2023" @default.
• W4385462511 type Work @default.
• W4385462511 citedByCount "0" @default.
• W4385462511 crossrefType "journal-article" @default.
• W4385462511 hasAuthorship W4385462511A5014286562 @default.
• W4385462511 hasAuthorship W4385462511A5023706702 @default.
• W4385462511 hasAuthorship W4385462511A5023916915 @default.
• W4385462511 hasAuthorship W4385462511A5030442889 @default.
• W4385462511 hasAuthorship W4385462511A5036606080 @default.
• W4385462511 hasAuthorship W4385462511A5041249091 @default.
• W4385462511 hasBestOaLocation W43854625111 @default.
• W4385462511 hasConcept C121608353 @default.
• W4385462511 hasConcept C126322002 @default.
• W4385462511 hasConcept C143998085 @default.
• W4385462511 hasConcept C197934379 @default.
• W4385462511 hasConcept C207103383 @default.
• W4385462511 hasConcept C2775930923 @default.
• W4385462511 hasConcept C2778715236 @default.
• W4385462511 hasConcept C29730261 @default.
• W4385462511 hasConcept C44249647 @default.
• W4385462511 hasConcept C509974204 @default.
• W4385462511 hasConcept C530470458 @default.
• W4385462511 hasConcept C71924100 @default.
• W4385462511 hasConcept C90924648 @default.
• W4385462511 hasConcept C95190672 @default.
• W4385462511 hasConceptScore W4385462511C121608353 @default.
• W4385462511 hasConceptScore W4385462511C126322002 @default.
• W4385462511 hasConceptScore W4385462511C143998085 @default.
• W4385462511 hasConceptScore W4385462511C197934379 @default.
• W4385462511 hasConceptScore W4385462511C207103383 @default.
• W4385462511 hasConceptScore W4385462511C2775930923 @default.
• W4385462511 hasConceptScore W4385462511C2778715236 @default.
• W4385462511 hasConceptScore W4385462511C29730261 @default.
• W4385462511 hasConceptScore W4385462511C44249647 @default.
• W4385462511 hasConceptScore W4385462511C509974204 @default.
• W4385462511 hasConceptScore W4385462511C530470458 @default.
• W4385462511 hasConceptScore W4385462511C71924100 @default.
• W4385462511 hasConceptScore W4385462511C90924648 @default.
• W4385462511 hasConceptScore W4385462511C95190672 @default.
• W4385462511 hasFunder F4320332000 @default.
• W4385462511 hasLocation W43854625111 @default.
• W4385462511 hasLocation W43854625112 @default.
• W4385462511 hasOpenAccess W4385462511 @default.
• W4385462511 hasPrimaryLocation W43854625111 @default.
• W4385462511 hasRelatedWork W1900595920 @default.
• W4385462511 hasRelatedWork W2036739911 @default.
• W4385462511 hasRelatedWork W2130616545 @default.
• W4385462511 hasRelatedWork W2224319365 @default.

• next